Mirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: Should You Buy?
The market expects Mirum Pharmaceuticals, Inc. (MIRM) to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2022. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor th...